JPWO2020044239A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020044239A5 JPWO2020044239A5 JP2021510199A JP2021510199A JPWO2020044239A5 JP WO2020044239 A5 JPWO2020044239 A5 JP WO2020044239A5 JP 2021510199 A JP2021510199 A JP 2021510199A JP 2021510199 A JP2021510199 A JP 2021510199A JP WO2020044239 A5 JPWO2020044239 A5 JP WO2020044239A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- receptor
- cells
- domain
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020003175 receptors Proteins 0.000 claims 12
- 102000005962 receptors Human genes 0.000 claims 12
- 210000004027 cells Anatomy 0.000 claims 8
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 5
- 210000003171 Lymphocytes, Tumor-Infiltrating Anatomy 0.000 claims 4
- 108091008153 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000038129 antigens Human genes 0.000 claims 4
- 108091007172 antigens Proteins 0.000 claims 4
- 210000002865 immune cell Anatomy 0.000 claims 4
- 102000006240 membrane receptors Human genes 0.000 claims 4
- 108020004084 membrane receptors Proteins 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 2
- 102100005826 CD19 Human genes 0.000 claims 1
- 101700087100 CD19 Proteins 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 210000004443 Dendritic Cells Anatomy 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 1
- 210000002540 Macrophages Anatomy 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 210000001616 Monocytes Anatomy 0.000 claims 1
- 238000004873 anchoring Methods 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 230000002147 killing Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
Claims (23)
b)自己切断ペプチド又は配列内リボソーム進入部位;及び
c)細胞表面受容体
をコードする核酸を含むベクター。 a) the erythropoietin (Epo) receptor;
b) a self-cleaving peptide or an internal ribosome entry site; and c) a vector comprising a nucleic acid encoding a cell surface receptor.
i)シグナルペプチド;
ii)標的細胞抗原に結合する細胞外受容体ドメイン;
iii)細胞の表面上の前記細胞外受容体ドメインを固定するヒンジ及び膜貫通ドメイン;並びに
iv)エフェクタードメイン
を含むキメラ抗原受容体である、請求項1~7のいずれか一項に記載のベクター。 The cell surface receptor is
i) a signal peptide;
ii) an extracellular receptor domain that binds to a target cell antigen;
iii) a hinge and transmembrane domain anchoring said extracellular receptor domain on the surface of a cell ; and iv) a chimeric antigen receptor comprising an effector domain. vector.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862724488P | 2018-08-29 | 2018-08-29 | |
US62/724,488 | 2018-08-29 | ||
PCT/IB2019/057217 WO2020044239A1 (en) | 2018-08-29 | 2019-08-27 | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021534770A JP2021534770A (en) | 2021-12-16 |
JPWO2020044239A5 true JPWO2020044239A5 (en) | 2022-09-02 |
Family
ID=69645138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021510199A Pending JP2021534770A (en) | 2018-08-29 | 2019-08-27 | Methods for specifically stimulating the survival and proliferation of genetically modified immune cells |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210324388A1 (en) |
EP (1) | EP3844186A4 (en) |
JP (1) | JP2021534770A (en) |
KR (1) | KR20210050540A (en) |
CN (1) | CN112601758A (en) |
AU (1) | AU2019330347A1 (en) |
SG (1) | SG11202101242VA (en) |
WO (1) | WO2020044239A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2839089T3 (en) | 2014-05-15 | 2021-07-05 | Nat Univ Singapore | Modified natural killer lymphocytes and their uses |
US11365236B2 (en) | 2017-03-27 | 2022-06-21 | Nkarta, Inc. | Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy |
BR112019020001A2 (en) | 2017-03-27 | 2020-04-28 | Nat Univ Singapore | stimulating cell lines for ex vivo expansion and activation of natural killer cells |
IL295888A (en) * | 2020-02-24 | 2022-10-01 | Us Health | Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer |
EP4319773A1 (en) * | 2021-04-06 | 2024-02-14 | Ensoma, Inc. | Modification of epor-encoding nucleic acids |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999067360A2 (en) * | 1998-06-25 | 1999-12-29 | Hemosol Inc. | Media and methods for expansion of erythroid stem cells for the production of hemoglobin |
CN1856506A (en) * | 2003-06-27 | 2006-11-01 | 株式会社载体研究所 | Method for transplanting lymphohematopoietic cells into mammal |
US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
AU2011377617B2 (en) * | 2011-09-23 | 2018-03-08 | Bluebird Bio, Inc. | Improved gene therapy methods |
WO2016118857A1 (en) * | 2015-01-23 | 2016-07-28 | Musc Foundation For Research Development | Cytokine receptor genes and the use thereof to enhance therapy |
-
2019
- 2019-08-27 CN CN201980055343.9A patent/CN112601758A/en active Pending
- 2019-08-27 WO PCT/IB2019/057217 patent/WO2020044239A1/en unknown
- 2019-08-27 JP JP2021510199A patent/JP2021534770A/en active Pending
- 2019-08-27 AU AU2019330347A patent/AU2019330347A1/en active Pending
- 2019-08-27 KR KR1020217008734A patent/KR20210050540A/en unknown
- 2019-08-27 SG SG11202101242VA patent/SG11202101242VA/en unknown
- 2019-08-27 US US17/267,617 patent/US20210324388A1/en active Pending
- 2019-08-27 EP EP19856119.3A patent/EP3844186A4/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Steinle et al. | Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family | |
CN105377886B (en) | High affinity binding molecules that recognize MAGE-A1 | |
JP2021191265A (en) | T-cell receptor recognizing mhc class ii-restricted mage-a3 | |
WO2019114235A1 (en) | Pdl1 monoclonal antibody and application thereof | |
Charron et al. | Analysis of HLA-D region-associated molecules with monoclonal antibody. | |
US10005845B2 (en) | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof | |
JP2020503885A5 (en) | ||
US20190336533A1 (en) | Chimeric antigen receptor and natural killer cells expressing same | |
Li et al. | Emerging roles for the FCRL family members in lymphocyte biology and disease | |
Mesci et al. | NKR-P1 biology: from prototype to missing self | |
JP2022141761A (en) | Transforming growth factor-beta responsive polypeptides and use methods thereof | |
US20210269502A1 (en) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment | |
CN105188358B (en) | The transgenic mice of chimeric MHC (MHC) the I quasi-molecules of expression | |
EP3411476B1 (en) | Enhanced production of immunoglobulins | |
JP2019514358A5 (en) | ||
JP2018528786A5 (en) | ||
Karaki et al. | Beta-chain broadens range of CD8 recognition for MHC class I molecule. | |
Karaki et al. | HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies | |
WO2021223604A1 (en) | T cell antigen receptor, multimeric complex thereof, and preparation method therefor and use thereof | |
EP1413316A1 (en) | Bifunctional conjugates or fusion proteins | |
JPWO2020044239A5 (en) | ||
Cook et al. | The Qa-1 alloantigens. II. Evidence for the expression of two Qa-1 molecules by the Qa-1d genotype and for cross-reactivity between Qa-1 and H-2K. | |
Morita et al. | TL antigen as a transplantation antigen recognized by TL-restricted cytotoxic T cells. | |
Noronha et al. | Generation and characterization of monoclonal antibodies to equine NKp46 | |
Harding et al. | MHC restriction of T-cell proliferative responses in Xenopus |